AntiCOVID-19 Vaccines for Children
DOI:
https://doi.org/10.14738/bjhmr.103.14737Keywords:
Children, COVID-19, Vaccine, Omicron strains, Influenza virusAbstract
Emergency use authorization of the COVID-19 vaccine to prevent coronavirus disease 2019 is reported from the Medical Letter on Drugs and Therapeutics as well as from the contradictions presented by the drug producers to FDA and CDC for the messanger RNA vaccines to be approved or authorized. According to the knowledge of the first SARS and of the MERS, the children were not exposed to the civet and to the camels as the adults. The children are infected by the virus whitout suffering a serious illness, but they are an important source of infection. There is no COVID-19 emergency among children: there is no increase in mortality. The risks of hospitalization for COVID-19 in children are very low and often concern children with other pathologies. The children’s detection of the congenital defect of the MTHFR mutation makes them hypersensitive to the vaccine for thrombotic manifestations. One myocarditis every 10.000 inoculations for young people means risking much more for the vaccine than for the virus.
References
COVID update: Bivalent vaccine booster doses authorized for children ≥5 years old. MED Lett Drugs Ther 64:e1, 2022.
COVID-19 update: Bivalent Pfizer and Moderna vaccines authorized for children ≥6 months old. . MED Lett Drugs Ther 64:e209, 2022.
FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Pfizer -BionTech COVID-19 vaccine and the Pfizer-BionTech COVID-19 vaccine, bivalent (original and Omicron BA4/BA.5) to prevent coronavirus disease 2019 (COVID-19). For 6 months through 4 years of age. March 14, 2023.
CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. March 16, 2023.
Arantes de Araújo L, Veloso CF, de Campos Souza M, Coelho de Azevedo JM and Tarro G. The potential impact of the COVID-19 pandemic on child growth and development: a systematic review. Running title: COVID-19 pandemic and child growth and development. Journal de Pediatria, 2020 DOI: 10.1016/ipd.2020.08.008.
Pierce C.A, Herold K.C, Herold B.C. Why is COVID-19 generally milder in childrenn? SCIENCE vol 377, issue 6611, p.1145, 2022.
Doshi P. Pfizer and Moderna’s “95% effective” vaccines—we need more details and the raw data. https://blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-needmore-details-and-the-raw-data/ , 2021
Jon Cohen. Studies reinforce the origin of the pandemic in Wuhan Animal Market. Science March 4, pp. 946-947, 2022.
Wu A. et al.Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host & Microbe, doi: 10.1016 / j.chom.2020.02. 001,2020.
Tarro G. The spread of the new coronavirus. Asian Journal of Science and Technology, Vol. 11, Issue 03, pp. 10865, March 2020.
Fan W. et al. A new coronavirus associated with human respiratory disease in China. Nature vol 579, 12 March 2020.
Mina M.J, Peto T. E, García-Fiñana M et al. “Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19”, The Lancet. Feb. 17, 2021.
Cao S, Gan Y, Wang C et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten milion residents of Wuhan, China. Nature Communications, 2021 https://www.nature.com/articles/s41467-020-19802-w
Smith C. . Scientists can’t explain puzzling lack of coronavirus outbreaks in Africa. BGR, September 4, 2020
Le Bert N, T Tan A, Kunasegaran K et al. Different pattern of pre-existing SARS-COV-2 specific T cell immunity in SARS-recovered and uninfected individuals. bioRxiv, 2020. Doi: https://doi.org/10.1101/2020.05.26. 115832.
Tarro G. Environment and Virus Interactions: Towards a Systematic Therapy of SARS-CoV-2. British Journal of Healthcare and Medical Research, 9(4). 253-260. 2022.
Tarro G. On the End of a Nightmare (COVID-19). The Role of the Immune System. British Journal of Healthcare and Medical Research, 9(6). 194-197, 2022. 109
Tarro G. Priorities and Threats of Antibiotic Resistance. British Journal of Healthcare and Medical Research, 9(6). 194-197, 2022.
Zhang L, Alexsia R, Khalil A et al. SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. BioRxiv, 2020.
Tarro G. Pros and Cons of COVID-19 Vaccines. British Journal of Healthcare and Medical Research, Vol -10(2). 141-146, 2023.
Tarro G. Western Season with Epidemic Flu, SARS-CoV-2 Omicron Strains and hRSV. British Journal of Healthcare and Medical Research, Vol - 10(2). 448-453, 2023
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Giulio Tarro
This work is licensed under a Creative Commons Attribution 4.0 International License.
